Resolution of Massive Tophaceous Gout with Three Urate-lowering Drugs

Nonspecific osteomyelitis of the spine (NOS) in a patient with primary gout due to Lesch–Nyhan syndrome (LNS): case description and literature review

“…Since radiographic changes in the spine are usually nonspecific in gout, trepanation biopsy and examination of the histological material with polarizing light are necessary to verify the diagnosis [11,12]. Subsequently, in accordance with the clinical recommendations for the treatment of gout, along with targeted antibiotic therapy for at least 4-6 weeks, the patient should receive xanthine oxidase inhibitors (to reduce the production of uric acid), as well as drugs to accelerate its excretion in normal renal function (probenecid) [28][29][30].…”

Hiperuricemia y gota: impacto de la ecografía

“…Incluso a los 2 años de haber iniciado el tratamiento hipouricemiante muchos enfermos con gota presentan tofos y signos de inflamación 28 . Por otro lado, el hallazgo de tofos y signos de inflamación obliga a que el tratamiento hipouricemiante se acompañe de una profilaxis adecuada para prevenir crisis de inflamación aguda, supuestamente desencadenadas por la reabsorción de los cristales de urato 29 . El seguimiento ecográfico, cuando se detectan tofos, permitiría conocer su evolución y establecer: a) la intensidad del tratamiento hipouricemiante, y b) si es aconsejable mantener un tratamiento preventivo de crisis de gota aguda 30 .…”

The Emerging Role of Biotechnological Drugs in the Treatment of Gout

“…Recently, some authors described the case of a patient with massive tophaceous gout that was concomitantly treated with 3 different ULTs, in particular allopurinol 600 mg/day, benzbromarone 100 mg/day, and 4 monthly rasburicase infusions that lead to the almost complete resolution of tophi before rasburicase withdrawal due to flushing and urticarial occurrence during the fifth infusion [ 100 ].…”